Dr. Chabner is a Professor of Medicine at Harvard Medical School, Clinical Director of the Cancer Center at Massachusetts General Hospital. With the formation of the Dana-Farber/Harvard Cancer Center, he also has responsibilities as Associate Director for Clinical Sciences of that consortium, which includes the Massachusetts General Hospital, Brigham & Women's Hospital, Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Dr. Chabner was previously at the National Cancer Institute ("NCI"), where he participated in the training of clinical and research fellows for 24 years and served for 13 years as permanent Director of the Division of Cancer Treatment, NCI. From 1971 to 1989, he maintained an active laboratory program in cancer pharmacology at the NCI, focusing on the mechanism of action and resistance of antifolates and other antimetabolites, and leading the development of paclitaxel (Taxol®). His research has contributed significantly to the development of high dose chemotherapy regimens and to standard therapies for lymphoma. He received an M.D., cum laude, from Harvard Medical School.